

**MO HEALTHNET DRUG UTILIZATION REVIEW BOARD**

**January 18, 2017**

**Department of Natural Resources, La Charrette/Nightengale Conference Rm, Jefferson City MO**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Randy Beckner, Pharm D  
Sandra Bollinger, Pharm D  
Stacey Mangum, Pharm D  
Charlene Heyde, RPh  
Ginger Nicol, MD

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Jenna McTeer, RN, Clinical Management  
Angela Wilson, Manager, Band I  
Dr. Timothy Kling, MD, Assistant Medical Director  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Elizabeth Short, Medicaid Specialist  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager

**DUR BOARD MEMBERS ABSENT**

Kenneth Haller, MD  
Glenn Talbot, MD  
Jennifer Passanise, FNP  
Kirk Nelson, MD

**CONTRACTED STAFF PRESENT**

Josh Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Rick Pope, Magellan

**OTHERS IN ATTENDANCE**

Rob Kilo, Biogen  
Lee Stout, Chiesi  
Teresa Blair, Ipsen  
Shefali Patel, Wipro  
Mike LaFond, AbbVie  
Evan Rushing, Alkermes  
Geri Roling, Wipro  
Chelsea Pendleton, Wipro  
Ashley Polce, Abbvie  
Berend Koops, Merck  
Brian Rose, Merck

Anne McNamara, Otonomy  
Tom Peddicord, Novartis  
Aaron Shaw, Boehringer - Ingelheim  
Steve Naert, Lilly  
Jennifer Stoffel, Janssen  
Terry McCurren, Otsuka America  
Eric Gardner, Vertex  
Chet Steckler, Purdue Pharma, LP  
Jim Baumann, Pfizer

<b>Welcome, Introductions and Opening Remarks</b>	Susan Abdel-Rahman, Pharm D, called the meeting to order. Stephen Calloway, RPh facilitated the meeting on behalf of the MO Health Net Division (MHD) beginning with introduction of new staff, Franky Moseley, AOSA and Mitch Ruth, Fiscal Unit Manager. *Members in attendance did not constitute a quorum. <i>Dr. Ginger Nicol had indicated she would attend by phone, but was unable to participate at the time of the meeting. It was agreed by the Chair that a quorum would be established by providing the meeting materials to Dr. Nicol afterwards and obtaining her vote on the decision items. *The minutes reflect a quorum with the inclusion of Dr. Nicol's meeting review and votes.</i>
<b>Minutes Review and Approval</b>	Minutes of the October 2016 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
<b>Pharmacy Program/Budget Update</b>	Stephen Calloway presented a brief PowerPoint including highlights and details of the Pharmacy Program. The presentation contained graphs representing an expenditure amount per member for all eligible participants, disabled participants, elderly participants, and other; a pie chart of participants; and expenditures by participants. The top four drug classes per FY were shared. Pharmacy expenditures were discussed, including Information on the Hepatitis C Expenditures FY 2015 thru FYTD 2017. Other program statistics were shared, along with discussion of pharmaceutical industry trends and observations. Calloway indicated MHD is working with other state agencies as part of the Prescription Drug Misuse Workgroup.
<b>Review of Prior Authorization Meeting</b>	Copies of the agenda and draft minutes, including public hearing, from the December 2016 <i>Drug Prior Authorization Committee Meeting</i> were included in the members' meeting packet.
<b>Old Business Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes and Clinical Edits was included in the Members' meeting packet and provided as a handout to all attending. . Renewed Therapeutic Classes approved in Dec/Jan will be implemented April 2017. Upcoming PDL decisions from Dec/Jan will be implemented April 2017. Schedules may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf</a>
<b>New Drug Review</b>	<p>Stephen Calloway reviewed the new drug products that were identified for the quarter April, May and June 2016 and the recommended status within the clinical program.</p> <ul style="list-style-type: none"> <li>• <b>Discussion</b> - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions.</li> <li>• <b>Decision</b> - The listing and recommendations were approved as part of a block vote by the DUR Board (See Roll Call Votes).</li> </ul>

<b>Clinical Edits</b>	
<b>Short-Acting Combination Narcotics Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway reviewed the Clinical Edit proposal, along with information on projected claims and call center impact. Implementation of the edit is not planned until 2017.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Botulinum Toxin Type A</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway reviewed the Clinical Edit proposal, along with information on projected claims and call center impact. Implementation of the edit is not planned until 2017.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Preferred Drug List (PDL) Annual Review</b>	
<b>Alzheimer’s Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> — Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antiemetic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cox-II Inhibitor Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Fibromyalgia</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>GI Motility Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Long-Acting Narcotics</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>Non-Ergot Dopamine Receptor Agonists</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> — Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>NSAID Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> –</li> </ul>
<b>Opiate Dependence Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>

<b>Opiate Emergency Reversal Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Sedative Hypnotic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Skeletal Muscle Relaxants</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Serotonin Receptor Agonists (Triptans)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Tramadol-Like Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Mr. Calloway presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Preferred Drug List Discussion/Therapeutic Classes</b>	A handout of therapeutic categories scheduled for Annual Review and Renewal on the Preferred Drug List at the March/April Advisory meetings was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page.

<b>Conduent Update</b>	Luke Boehmer, Pharm D reviewed clinical edits.
<b>Top 25 Drugs by Cost</b>	Dr. Boehmer reviewed the Top 25 Drugs Summary Reports for the 3 <sup>rd</sup> quarter 2015 through the 2 <sup>nd</sup> quarter 2016. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Call Center Statistics Clinical Edit Summary Report</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were shared. Dr. Boehmer reviewed how many sites/physical locations are trained and have access to CyberAccess. Reports also detailed the number and type of prescribers and active users on CyberAccess. Board members were also updated on approved, denied, and total Prior Authorizations for New Drugs in August and September 2016, as well as PA transaction counts by PDL and Clinical Edit.
<b>Adjourn</b>	Charlene Heyde, RPh, made a motion to close this meeting under Section 610.021(14), (5) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. At the conclusion of these discussions the group adjourned entertaining no further business, actions or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for April 19, 2017.

**Roll Call Votes – January 18, 2017**

<b>MEMBER</b>	<b>MEETING MINUTES</b>	<b>ALL RECOMMENDATIONS BLOCK VOTE</b>	<b>CLOSED SESSION</b>	<b>ADJOURN</b>
Susan Abdel-Rahman, Pharm D	MY	MY	Y	MY
Charlene Heyde, RPh	Y	SY	MY	SY
Sandra Bollinger, Pharm D	Y	Y	Y	Y
Kenneth Haller, MD	-	-	-	-
Glenn Talboy, MD	-	-	-	-
Jennifer Passanise, FNP	-	-	-	-
Stacy Mangum, Pharm D	SY	Y	SY	Y
Kirk Nelson, MD	-	-	-	-
Ginger Nicol, MD	Y	Y	Y	Y
Randy Beckner, Pharm D	Y	Y	Y	Y

**EXECUTIVE SESSION**  
**January 18, 2017**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Randy Beckner, Pharm D  
Sandra Bollinger, Pharm D  
Stacey Mangum, Pharm D  
Charlene Heyde, RPh

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Jenna McTeer, RN, Clinical Management  
Angela Wilson, Manager Band I  
Timothy Kling, MD, Assistant Medical Director EBU  
Franki Moseley, Administrative Office Support Assistant  
Elizabeth Short, Medicaid Specialist  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager

**DUR BOARD MEMBERS ABSENT**

Kenneth Haller, MD  
Glenn Talboy, MD  
Jennifer Passanise, FNP  
Kirk Nelson, MD  
Ginger Nicol, MD

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Kathleen Wilbers, Pharm D, Conduent  
Rick Pope, Pharm D, Magellan

Minutes Review	Minutes of the October Executive Session were approved as submitted.
Case Reviews	Jenna McTeer, RN reviewed 1 case.
Adjourn	Executive session adjourned.